Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 0042 • ACR Convergence 2024
Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model
Eva Philippon¹, Jan Piet van Hamburg¹, Lisanne van Rooijen¹, Gary Sims², Conny Van der Laken³ and Sander Tas⁴, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
Abstract Number: 0059 • ACR Convergence 2024
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Susanna R. Bidgood¹, Sophie Hopkin¹, Kathryn R. Malpas¹, David M. Kallenberg¹, Jacqueline O’Neill¹, Geofrey Odede¹, Bernard Lauwerys², Baran Ufuktepe³ and David Humphreys¹, ¹UCB Biopharma UK, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³UCB Pharma, Istanbul, Turkey
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
Abstract Number: 0144 • ACR Convergence 2024
More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups
John Chen¹, Tanya Selvam¹, Jeanne Darbinian², Christopher Macko¹, Nirmala Ramalingam², Joan Lo² and Lucy Liu², ¹Kaiser Permanente Oakland Medical Center, Oakland, CA, ²Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a disabling, autoimmune condition affecting up to as many as 17.6 million individuals worldwide. Epidemiologic evidence in the United States…
Abstract Number: 0227 • ACR Convergence 2024
Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study
Julio Ramírez¹, Vicenç Torrente-Segarra², Andrea Cuervo³, Mireia Moreno⁴, Ana Belén Azuaga¹, Lourdes Mateo⁵, Beatriz Frade-Sosa⁶, Andrea Zacarias¹, Noemí Busquets Pérez⁷, Susana Holgado⁸, Paula Estrada-Alarcón⁹, Delia Reina¹⁰, Juan José De Agustín¹¹, Carme Moragues¹², María Bonet¹³, Sandra Farietta¹, Patricia Corzo¹, Andrés Ponce¹⁴, Virginia Ruiz Esquide¹, Lucia Alascio¹ and Juan Cañete¹⁵, and ECOCAT group, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³Hospital General Granollers, Granollers, Spain, ⁴Hospital Parc Taulí, Sabadell, Spain, ⁵Hospital Germans Trias i Pujol, Badalona, Spain, ⁶Hospital Clínic, Barcelona, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Hospital Moises Broggi, Barcelona, Spain, ¹¹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹²Hospital Bellvitge, Barcelona, Spain, ¹³Hospital Alt Penedés i Garraf, Barcelona, Spain, ¹⁴Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ¹⁵Hospital Clinic an IDIBAPS, Barcelona, Spain
Background/Purpose: The ultrasound (US) finding of proliferative synovitis (PS) in Rheumatoid Arthritis (RA), is associated with ACPA, erosions and changes in therapy [1]. However, no…
Abstract Number: 0369 • ACR Convergence 2024
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Simonetta van Griethuysen¹, Quirine Dumoulin² and Annette van der Helm-van Mil³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
Abstract Number: 0463 • ACR Convergence 2024
Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis
Jose Antonio Davila Jimenez¹, Dionicio Galarza-Delgado², Iris Jazmín Colunga Pedraza³, jose Ramon Azpiri-Lopez⁴, Rosa Icela Arvizu-Rivera³, Jesus Cardenas-de la Garza⁵, Aleydis Gonzalez Melendez³, Andrea Guajardo Aldaco³, Maria F. Elizondo-Benitez⁶, Rebeca L. Polina-Lugo³ and Diego Salcedo-Almanza⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁷Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 0497 • ACR Convergence 2024
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Adrián Quevedo-Rodríguez¹, Marta Hernández-Díaz², Dara Rodríguez-González2², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴, Agustín F González-Rivero², Elena González López⁵, gonzalo Ocejo-Viñals⁵, Miguel Angel Gonzalez-Gay⁶ and ivan Ferraz-Amaro⁷, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
Abstract Number: 0513 • ACR Convergence 2024
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting
Ioasaf Karafotias¹, Maryam Adas¹, Katie Bechman¹, Nicholas Williamson¹, Mark Hughes¹, Daksh Mehta², Ritika Roy¹, Sam Norton³ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, England, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Sama Hajizadeh¹, Tyson Barrett², Yue Yin³ and Dr Tarun Sharma⁴, ¹Allegheny Health Network, Pittsburgh, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, ⁴West Penn Hospital, Pittsburgh, PA
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
Abstract Number: 0802 • ACR Convergence 2024
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Xiaosong Wang⁴, Misti Paudel⁵, Emily Kowalski³, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni³, Caleb Bolden⁶, Tina Mahajan⁷, Erica Mulcaire-Jones⁸, Neda Kortam⁸, Pierre-Antoine Juge⁹, Tracy J Doyle¹⁰, Zachary Wallace¹¹, Marcy Bolster⁶, Kevin Deane¹², Dinesh Khanna⁸, Bryant England⁷ and Jeffrey Sparks¹³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Michigan, Ann Arbor, MI, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital, West Roxbury, MA, ¹¹Massachusetts General Hospital, Newton, MA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
Abstract Number: 0896 • ACR Convergence 2024
Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB
Michelle Morency¹, Taehyeung Kim¹ and Peter Nigrovic², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a prevalent autoimmune disease in which aberrant immune attacks on joints and other tissues leads to permanent and disabling injury.…
Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].